Hepion Pharmaceuticals, Inc.

OPTIMI HEALTH CORP

HCW Biologics

Silexion Therapeutics

Vida Global

GCL Global

BiomX

MetaVia

Micware

MicroAlgo

426CVR015TMP

COEP

NBSE.ESC

SBIO

A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.

Pharmaceutical Technology

Coeptis Therapeutics

ESC NEUBASE THERAPEUTI

SEELOS THERAPEUTICS INC

Seelos Therapeutics

iShares Biotechnology ETF

Ark Genomic Revolution ETF

Invesco Biotechnology & Genome ETF

Direxion S&P Biotech Bull 3X

Invesco Nasdaq Biotechnology ETF

Proshares Ultra Nasdaq Biotech

First Trust NYSE Arca Biotech Index Fd

VanEck Biotech ETF

SPDR S&P Biotech

ALPS Medical Breakthrough

Seaport ENT

Seaport and Hemab target $180m IPOs as biotech listings accumulate

AMIX

Hemostemix Raises $784,000 to Advance Stem Cell Therapy Commercialization

Tip Ranks

Autonomix Medical

Direxion S&P Biotech Bear 3X

Hemostemix Raises $784,000 to Advance Stem Cell Therapy Commercialization

Hemostemix Inc. (TSXV: HEM) announced that CEO Thomas Smeenk and Chairman Peter Lacey are attending the 2026 Abundance360 Summit in Los Angeles. They will discuss their regenerative treatment, ACP-01 (VesCell), aimed at improving health span through enhanced microvascular circulation. The treatment has shown promise in clinical studies for various heart conditions. Smeenk highlighted the significant interest in commercializing ACP-01 in Florida and The Bahamas, emphasizing its potential impact on longevity and health outcomes. Hemostemix is known for its autologous stem cell therapy platform and has received recognition for its innovative approach.

StockTitan

iShares US Medical Devices

VG Health

SPDR S&P Health Equip

Health Care Select Sector SPDR

iShares US Pharma

iShares Global Healthcare

Hemostemix Leadership Attending Abundance360 Summit | HMTXF Stock News

HEPA

Psychedelic biotechs are advancing towards Phase 3 trials, with five companies focusing on CNS treatments for depression and anxiety. Helus Pharma announced on February 27, 2026, that pivotal trials are progressing towards regulatory approval, offering hope for patients who have not responded to traditional therapies. This marks a significant shift in mental health care, potentially leading to new effective treatment options for those suffering from these conditions.

Unusual Whales